Pharmaceutical developer Johnson & Johnson is seeking emergency use authorization from the Food and Drug Administration for its COVID-19 booster vaccine for people 18 years and older.

The company claims that a booster dose given six months after the initial one-dose regimen increases antibodies 12 times during the first month following administration of the booster and is 94% effective against symptomatic infection.